Valirx Share Discussion Threads

[francoismyname] 22/2/2022 08:35

£16m market cap.

WTF

But Suzys doing a great job

[rainmaker] 17/2/2022 12:54

Incredibly despite last week's meteoric rise, Vector Capital are only trading at a small premium to their net working capital of 51p a share- consider this figure a proxy for the Company's minimum liquidation value yet IMHO the Company is trading very profitably, currently pays a 4.1% historic dividend yield and forecast to be increased,in a strong niche market of providing bridging loans to developers converting large houses to flats, commercial and retail building to residential use where there is a real structural shortage and rising prices. Last August the Government further relaxed planning rules to expedite such projects by removing bureaucracy and red tape.IMHO the Company has a bright future and a trading update late last month has them trading ahead of expectation, with an increased order book and an enlarged debt facility. I wish all investing decisions were this easy.I expect them to one of the best performing shares on the IC list.

AIMHO, DYOR as I have done mine

regards

RM

[rainmaker] 17/2/2022 12:28

Re Vector Capital-After the initial mad rush to buy late last week after they appeared in the IC Bargain Portfolio and traded as high as 62.90p, now currently 53p/56p with a constant stream of buyers and IMHO a good entry point for long term holders.

AIMHO, DYOR as I have done mine

regards

RM

[rainmaker] 17/2/2022 11:50

hxxps://goodmoneyguide.com/dma-brokers/

best wishes

[rainmaker] 17/2/2022 11:44

I don't think any Value investor would disagree that the strategy predominantly involves investing in small cap companies where the opportunities to exploit your comprehensive and thorough research are greatest- amongst the unloved, the down at heel,the neglected, the ugly in the first instance, the misunderstood, the under researched but to the convesrted its an incredible strategy that delivers higher returns at below market risk.


However wide dealing spreads ie the difference between a share's bid and offer can be a real problem for Stockmarket Value Investors so I urge anyone dealing in reasonable volumes on a regular basis to explore the possibility of opening a Direct Market Access(DMA)account because it will significantly reduce your dealing costs and improve your returns.I don't know of any Value Investors trading on margin and this will make it easier for you to qualify for DMA.

If you are purchasing £10k of a share then expect a 1% commission charge through a no frills, execution only discount broker so a £100 charge but purchased electronically through a DMA Broker you will pay as little as £6 for the same trade so obviously a huge saving in commission but it gets even better than that. Direct Market Access(DMA) allows you to enter your bid at the bid price (and your offer at the offer price)and it will appear on the London Stock Exchange electronic order book.So DMA can allow you to buy at the bid price and sell at the offer price and to escape paying the market makers onerous spread so you'll appreciate the huge inherent cost savings. You'll need Level 2 facility to see all the bids and offers with volumes for a stock and this will cost you circa £17 a month but this will be rebated in full if your're dealing on a regular basis.I'll post a list of DMA Brokers later.

AIMHO, DYOR

regards

RM

[rainmaker] 17/2/2022 10:39

Hi Netcurtains, did you buy the latest copy of the Investors Chronicle?They have their annual bargain portfolio for 2022 in this issue. If you want a copy you'll need to find one today as the new copy will come out tomorrow or friday. Their 1 year portfolio performances have beaten the bench mark FTSE All-Share Index in 19 out of the last 23 years and sometimes by a staggeringly wide margin eg 2003, a 146% annual return v 29% of the market and there are more than a few years where their returns are double or even triple the market returns. Their longer period multi year returns are excellent. However they sometimes stretch the criteria to include some Companies with net working capital of just 30% of market cap.If you can't find a copy PM and I will try to get a copy to you.

regards

[412069] 17/2/2022 08:45

Are you selling then sooty if not by the end of the month ?
A cracking investment theory that sell out before news, works every time that one i bet ha.

[sooty snipes] 16/2/2022 19:56

Here we are less than two weeks off March yet Suzy was saying a deal should be concluded by year end 2021. I'm beginning to get a bit twitchy now. To be out by a couple of weeks is one thing but we are now almost seven weeks into new year. This deal needs to be over the line by end of February

[jasonpugh] 15/2/2022 08:10

Cenkos issues new note. Remains recommend buy.

[francoismyname] 14/2/2022 21:51

Just get the main deal done now. Nothing else will do.

[412069] 14/2/2022 15:08

Worth holding tight then nico.

[nico115] 14/2/2022 14:58

With today's news I think our Uni tie ups are worth the current mkt capMeaning we get all the legacy products for nothing

[412069] 14/2/2022 07:59

Yet another feather in our cap.
And still the big deal to come.

[uknighted] 14/2/2022 07:30

ValiRx PLC ("ValiRx" or the "Company")

Evaluation agreement with University of Barcelona

ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered into an evaluation agreement with University of Barcelona (Spain) to investigate a drug candidate for use in oncology.

Under the agreement, the Company will carry out a defined series of preclinical tests on a lead series of peptidomimetic drug candidate molecules over the next twelve months to validate the technology and determine suitability for commercialisation. This preclinical evaluation, the cost of which will be borne by ValiRx of up to GBP100,000, will investigate the mode of action and potential utility as a treatment of KRAS (a GTPase protein made by the oncogene, Kirsten Rat Sarcoma Virus) dependent cancers including Uterine and Pancreatic Cancers.

At the conclusion of the evaluation period (February 2023), the Company has an option to license the technology on pre-agreed terms.

Dr Suzy Dilly, CEO of ValiRx commented: "The lead series of drug candidates under evaluation in this agreement have been developed towards a novel interaction with the KRAS protein important in many cancers of high unmet medical need. KRAS has been a target of interest in oncology for a number of years, and this project has potential to provide a unique method to impact this important pathway."

University of Barcelona research group's Principal Investigator: "KRAS is a known therapeutic target for several cancers, but until recently, it has been undruggable. However, we have found a way to interact with this target. The partnership between University of Barcelona and ValiRx is essential to accelerate the development of those promising results that we have achieved. This agreement will reinforce the project and provide valuable data to progress towards clinical development."

[uknighted] 14/2/2022 07:29

RNS
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered into an evaluation agreement with University of Barcelona (Spain) to investigate a drug candidate for use in oncology.

[spob] 11/2/2022 21:23

Benjamin Graham NCAV Bargain Screen (as used in IC Bargain share portfolios but Inverted)


NCAV = Current Assets - Total Liabilities

NCAV ratio = Mcap/NCAV (less than 0.66 gives a Graham NCAV bargain with 33% margin of safety)

* Note, IC bargain ratios are inverted, ie NCAV/Mcap (>1.5 = Graham bargain)

This is a deep value screen based on Ben Graham's writings. It is a simplistic screen which just looks for stocks where the market cap is less than net current asset value. It is not to be confused with his more involved Enterprising Investor and Defensive Investor criteria which have been modelled separately. As a reminder, NCAV = Current Assets - Total Liabilities. That's a stringent requirement, since most companies have negative NCAVs but Graham was looking for firms trading so cheap that there was little danger of falling further. In addition, Graham would have requested a margin of safety of at least 33%, so his P/NCAV threshold would have been 0.66. Graham argued such companies were typically priced at significant discounts to the likely value that stockholders could receive in an actual sale or liquidation of the entire corporation. Because of the kind of unloved/troubled companies it generates, this is not a strategy for the faint-hearted. Graham sought safety from individual bankruptcy risk by diversifying his portfolio with a large numbers of companies – he suggested 30.

[spob] 11/2/2022 21:13

Investors Chronicle - semi bargain portfolio




.

.




Tavistock Investments TAVI
Vector Capital VCAP
H&T HAT
Tekcapital TEK
Billington BILN
Conygar CIC
Henry Boot BOOT
Sylvania Platinum SLP

[nico115] 11/2/2022 14:51

Thx RMChat later

[rainmaker] 11/2/2022 11:52

Please correct me if I'm wrong but if I remember correctly Walker Crips have FUM of £5.4bln and £3.4bln was the average FUM but maybe you're just building a further margin of safety by using a conservative figure. However regardless of which figure, I'm sure we can both agree that the WC Fund Manager business affords us a substantial margin of safety that all Value Investors demand whether it be £5.4ln to give an intrinsic value of £216mln or 468p a share or its £3.5bln to arrive at a figure of £140mln or 303p a share.With a CEO who owns 29.20% of the Company, I expect them to be taken private this year. I will try to buy more with a further 15,000 tomorrow.

I would urge Arthur to rethink and fellow Readers to investigate Vector Capital(VCAP). I predicted that they would be included in the IC Bargain Portfolio and its absolutely no surprise its there, as its a strong and profitable niche business with a good returns and 5/6% dividend yield yet trading at less than liquidation value as measured by net working capital but IMHO has a bright future. It provides bridging loans to developers converting commercial/retail properties to residential. With the increasing success and dominance of e-commerce and the widely reported death of the High Street has meant a glut of unlet commercial premises but there is a shortage of residential properties in a booming msrket. Government legislation introduced last August has made it even easier to cut through bureaucracy and red tape in planning change of use so I expect this established trend to accelerate. Vector Capital had a trading update late last month and is trading ahead of expectations, with an increase in its loan book and borrowing facility.

AIMHO, DYOR as I have done mine

regards

[412069] 10/2/2022 09:12

Not Suzy tho, she will once the deals signed.

[francoismyname] 10/2/2022 09:04

Drip drip drip.

You know the scenario here . The company has never delivered anything on bleeding time . At least the directors over the years have all been well remunerated .

[nico115] 07/2/2022 15:37

Thanks ,interesting Will chat to rainmaker later about it

[zangdook] 07/2/2022 12:16

Asian Citrus is listed in Hong Kong, code 73. There's a barely active board for it here under the defunct AIM code ACHL.

[nico115] 07/2/2022 12:09

Yes came across wrongly I apologise RM is one of the best Was interested as so nearly bought